Literature DB >> 15277254

Primary chemotherapy for breast cancer: the evidence and the future.

M S Mano1, A Awada.   

Abstract

The first generation of randomised trials assessing the role of primary chemotherapy in breast cancer has failed to demonstrate the expected survival benefit. However, it has established the role of this treatment in 'downstaging' tumours of patients with locally advanced disease and, consequently, in improving breast conservation rates. Also, a number of surrogates of outcome have been identified, which will hopefully lead to earlier results in breast cancer clinical trials. Encouraging results have also been reported in trials investigating a number of novel approaches. Copyright 2004 European Society for Medical Oncology

Entities:  

Mesh:

Year:  2004        PMID: 15277254     DOI: 10.1093/annonc/mdh302

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  5 in total

Review 1.  Early breast cancer.

Authors:  Tomoyoshi Suzuki; Masakazu Toi; Shigehira Saji; Kazumi Horiguchi; Tomoyuki Aruga; Eiji Suzuki; Shinichiro Horiguchi; Nobuaki Funata; Katsuyuki Karasawa; Noriko Kamata
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 2.  [Neoadjuvant treatment and breast conserving surgery - a success of clinical research in breast cancer].

Authors:  Michael Gnant
Journal:  Wien Med Wochenschr       Date:  2010-04

3.  Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.

Authors:  A Halim; H Wahba
Journal:  Med Oncol       Date:  2011-02-25       Impact factor: 3.064

4.  Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.

Authors:  Yesim Eralp; Terry L Smith; Kadri Altundağ; Shu-Wan Kau; Jennifer Litton; Vicente Valero; Aman Buzdar; Gabriel N Hortobagyi; Banu Arun
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-26       Impact factor: 4.553

Review 5.  Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.

Authors:  Chen Li; Yan Wang; Yueqing Gong; Tengrui Zhang; Jiaqi Huang; Zhen Tan; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2021-03-24       Impact factor: 6.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.